These conditions include many of the autoimmune diseases, such as rheumatoid arthritis, lupus, and several rare autoimmune conditions. Some diseases, such as multiple sclerosis, have deleterious antibodies as only one factor. In these cases, this technology might help to mitigate or partially relieve symptoms.

The principle on which the drug technology is based was established in the scientific literature in 1969. While several treatments were developed and effective in cell cultures, these early formulations were unsafe and never used in humans or animals. With the recent discovery of molecules with extremely specific activity and proven safety, the Institute for Applied Biomedicine was able to modify the original formulations for use in humans.

The Institute has experimental evidence, from its own work and that of other labs and companies, that its immune-modifying drug technology will be both safe and effective. We are developing drugs for several autoimmune conditions, and will proceed with the development of others as soon as funding and internal capacity allow (see Drug Development Plans).

If you are interested in learning more about our treatments for immune system diseases, or in supporting or speeding our progress on a particular disease, please Contact Us or Support Our Research.

Drug Development Plans     Support Our Research     Contact Us